MX370140B - Derivado de 2-acilaminotiazol o sal del mismo. - Google Patents

Derivado de 2-acilaminotiazol o sal del mismo.

Info

Publication number
MX370140B
MX370140B MX2016016134A MX2016016134A MX370140B MX 370140 B MX370140 B MX 370140B MX 2016016134 A MX2016016134 A MX 2016016134A MX 2016016134 A MX2016016134 A MX 2016016134A MX 370140 B MX370140 B MX 370140B
Authority
MX
Mexico
Prior art keywords
bladder
urinary
muscarinic
treatment
tract diseases
Prior art date
Application number
MX2016016134A
Other languages
English (en)
Other versions
MX2016016134A (es
Inventor
Maeda Jun
Negoro Kenji
Takahashi Taisuke
Tanaka Hiroaki
Yokoyama Kazuhiro
takamatsu Hajime
Koike Takanori
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016016134A publication Critical patent/MX2016016134A/es
Publication of MX370140B publication Critical patent/MX370140B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se proporciona un compuesto el cual es útil como un ingrediente activo para una composición farmacéutica para prevenir o tratar la disfunción en el almacenamiento de orina, disfunción en la evacuación, disfunción del tracto urinario inferior y similares. Los presentes inventores han descubierto que un derivado de tiazol sustituido con pirazinilcarbonilamino en la posición 2 es un excelente modulador alostérico positivo del receptor muscarínico M3 y se pronostica como un agente para prevenir o tratar enfermedades de la vejiga / tracto urinario asociadas con las contracciones de la vejiga por un receptor M3 muscarínico, completando así la presente invención. El derivado de 2-acilaminotiazol o una sal del mismo de la presente invención se espera que tenga utilidad como un agente para prevenir o tratar enfermedades de la vejiga/tracto urinario asociadas con las contracciones de la vejiga por un receptor M3 muscarínico, por ejemplo disfunción en la evacuación tal como vejiga hipoactiva y similares. t.
MX2016016134A 2014-06-06 2015-06-05 Derivado de 2-acilaminotiazol o sal del mismo. MX370140B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06
PCT/JP2015/066321 WO2015186821A1 (ja) 2014-06-06 2015-06-05 2-アシルアミノチアゾール誘導体またはその塩

Publications (2)

Publication Number Publication Date
MX2016016134A MX2016016134A (es) 2017-03-08
MX370140B true MX370140B (es) 2019-12-03

Family

ID=54766887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016134A MX370140B (es) 2014-06-06 2015-06-05 Derivado de 2-acilaminotiazol o sal del mismo.

Country Status (34)

Country Link
US (2) USRE49111E1 (es)
EP (1) EP3153511B1 (es)
JP (1) JP6319436B2 (es)
KR (1) KR102482844B1 (es)
CN (2) CN106414438B (es)
AR (1) AR100748A1 (es)
AU (1) AU2015269449B2 (es)
BR (1) BR112016028270B1 (es)
CA (1) CA2950564C (es)
CO (1) CO2017000044A2 (es)
CY (1) CY1122290T1 (es)
DK (1) DK3153511T3 (es)
EA (1) EA031866B1 (es)
ES (1) ES2732066T3 (es)
HR (1) HRP20190943T1 (es)
HU (1) HUE043496T2 (es)
IL (1) IL249356B (es)
LT (1) LT3153511T (es)
MA (1) MA39950B1 (es)
ME (1) ME03438B (es)
MX (1) MX370140B (es)
MY (1) MY197712A (es)
NZ (1) NZ727142A (es)
PH (1) PH12016502405A1 (es)
PL (1) PL3153511T3 (es)
PT (1) PT3153511T (es)
RS (1) RS58809B1 (es)
SA (1) SA516380427B1 (es)
SG (2) SG10202000463YA (es)
SI (1) SI3153511T1 (es)
TR (1) TR201908676T4 (es)
TW (2) TWI689507B (es)
UA (1) UA122208C2 (es)
WO (1) WO2015186821A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103110B1 (en) 2006-12-20 2014-03-26 GVBB Holdings S.A.R.L Embedded audio routing switcher
CA2959290A1 (en) 2014-08-26 2016-03-03 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
WO2018116139A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
JPWO2019189766A1 (ja) * 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
CN111718293A (zh) * 2019-03-18 2020-09-29 持田制药株式会社 双芳基酰胺衍生物的制造方法
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
WO2024122076A1 (ja) * 2022-12-09 2024-06-13 株式会社旭飛薬業 体液調節剤、体液調節用組み合わせ剤及び化合物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2001278872A (ja) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
WO2001090081A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
WO2003037862A1 (fr) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Derives amide, et medicaments correspondants
ES2416304T3 (es) 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1647553A4 (en) 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
KR101764952B1 (ko) * 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽

Also Published As

Publication number Publication date
CN106414438B (zh) 2019-12-31
BR112016028270A2 (pt) 2022-07-19
IL249356B (en) 2019-11-28
BR112016028270B1 (pt) 2023-05-02
SI3153511T1 (sl) 2019-08-30
CA2950564A1 (en) 2015-12-10
MA39950A (fr) 2017-04-12
USRE49111E1 (en) 2022-06-21
SG11201610201UA (en) 2017-01-27
JPWO2015186821A1 (ja) 2017-04-20
ME03438B (me) 2020-01-20
KR20170013987A (ko) 2017-02-07
US20170197955A1 (en) 2017-07-13
WO2015186821A1 (ja) 2015-12-10
IL249356A0 (en) 2017-02-28
NZ727142A (en) 2022-10-28
CO2017000044A2 (es) 2017-03-31
MY197712A (en) 2023-07-09
UA122208C2 (uk) 2020-10-12
TWI745877B (zh) 2021-11-11
CY1122290T1 (el) 2021-01-27
CN110845490A (zh) 2020-02-28
CN106414438A (zh) 2017-02-15
HRP20190943T1 (hr) 2019-09-20
DK3153511T3 (da) 2019-06-24
HUE043496T2 (hu) 2019-08-28
PH12016502405B1 (en) 2017-02-20
TWI689507B (zh) 2020-04-01
AR100748A1 (es) 2016-10-26
MA39950B1 (fr) 2019-08-30
AU2015269449B2 (en) 2019-03-14
TR201908676T4 (tr) 2019-07-22
BR112016028270A8 (pt) 2023-01-17
CN110845490B (zh) 2023-03-28
SA516380427B1 (ar) 2019-11-28
PH12016502405A1 (en) 2017-02-20
EA201692469A1 (ru) 2017-05-31
EP3153511A4 (en) 2017-12-06
PT3153511T (pt) 2019-06-28
EP3153511B1 (en) 2019-05-15
ES2732066T3 (es) 2019-11-20
EA031866B1 (ru) 2019-03-29
EP3153511A1 (en) 2017-04-12
LT3153511T (lt) 2019-07-10
JP6319436B2 (ja) 2018-05-09
US9951060B2 (en) 2018-04-24
PL3153511T3 (pl) 2019-09-30
MX2016016134A (es) 2017-03-08
TW201613914A (en) 2016-04-16
KR102482844B1 (ko) 2022-12-30
CA2950564C (en) 2023-03-07
SG10202000463YA (en) 2020-02-27
AU2015269449A1 (en) 2016-12-22
TW202026294A (zh) 2020-07-16
RS58809B1 (sr) 2019-07-31

Similar Documents

Publication Publication Date Title
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
SA515360956B1 (ar) مشتق من 2-أسيل امينو ثيازول أو ملح من أملاحه
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201692298A1 (ru) Производные карбоксамидов
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
UA116243C2 (uk) Гетероциклічна ацетамідна сполука
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2017002500A (es) Derivado de 2-aminotiazol o sal del mismo.
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators
PH12016502247A1 (en) Carboxamide derivatives
TH178650B (th) อนุพันธ์ 2-แอซิลอะมิโนไธอะโซล (2-acylaminothiazole) หรือเกลือของพวกมัน

Legal Events

Date Code Title Description
FG Grant or registration